A Phase II Study of Chidamide or Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer

NCT01836679 Phase 2 COMPLETED

The purpose of this study is to evaluate the efficacy and safety of Chidamide combined with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

Details

Lead sponsor	Chipscreen Biosciences, Ltd.
Phase	Phase 2
Status	COMPLETED
Enrolment	124
Start date	2013-04
Completion	2015-12

Conditions

• Non-small-cell Lung Cancer

Interventions

• Chidamide
• Paclitaxel
• Carboplatin
• Placebo

Primary outcomes

• Progression-Free Survival (PFS) — From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 76 weeks
  PFS is measured from the start of treatment until progression or death,whichever is first met

Countries

China